Literature DB >> 21263156

Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria.

Mary E D Flowers1, Yoshihiro Inamoto, Paul A Carpenter, Stephanie J Lee, Hans-Peter Kiem, Effie W Petersdorf, Shalini E Pereira, Richard A Nash, Marco Mielcarek, Matthew L Fero, Edus H Warren, Jean E Sanders, Rainer F Storb, Frederick R Appelbaum, Barry E Storer, Paul J Martin.   

Abstract

Risk factors for grades 2-4 acute graft-versus-host disease (GVHD) and for chronic GVHD as defined by National Institutes of Health consensus criteria were evaluated and compared in 2941 recipients of first allogeneic hematopoietic cell transplantation at our center. In multivariate analyses, the profiles of risk factors for acute and chronic GVHD were similar, with some notable differences. Recipient human leukocyte antigen (HLA) mismatching and the use of unrelated donors had a greater effect on the risk of acute GVHD than on chronic GVHD, whereas the use of female donors for male recipients had a greater effect on the risk of chronic GVHD than on acute GVHD. Total body irradiation was strongly associated with acute GVHD, but had no statistically significant association with chronic GVHD, whereas grafting with mobilized blood cells was strongly associated with chronic GVHD but not with acute GVHD. Older patient age was associated with chronic GVHD, but had no effect on acute GVHD. For all risk factors associated with chronic GVHD, point estimates and confidence intervals were not significantly changed after adjustment for prior acute GVHD. These results suggest that the mechanisms involved in acute and chronic GVHD are not entirely congruent and that chronic GVHD is not simply the end stage of acute GVHD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21263156      PMCID: PMC3062319          DOI: 10.1182/blood-2010-08-302109

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  40 in total

Review 1.  Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter?

Authors:  M Körbling; P Anderlini
Journal:  Blood       Date:  2001-11-15       Impact factor: 22.113

2.  Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors.

Authors:  H Glucksberg; R Storb; A Fefer; C D Buckner; P E Neiman; R A Clift; K G Lerner; E D Thomas
Journal:  Transplantation       Date:  1974-10       Impact factor: 4.939

3.  Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age.

Authors:  C Kollman; C W Howe; C Anasetti; J H Antin; S M Davies; A H Filipovich; J Hegland; N Kamani; N A Kernan; R King; V Ratanatharathorn; D Weisdorf; D L Confer
Journal:  Blood       Date:  2001-10-01       Impact factor: 22.113

4.  Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis.

Authors:  C Cutler; S Giri; S Jeyapalan; D Paniagua; A Viswanathan; J H Antin
Journal:  J Clin Oncol       Date:  2001-08-15       Impact factor: 44.544

5.  Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation.

Authors:  Paul J Martin; George B McDonald; Jean E Sanders; Claudio Anasetti; Frederick R Appelbaum; H Joachim Deeg; Richard A Nash; Effie W Petersdorf; John A Hansen; Rainer Storb
Journal:  Biol Blood Marrow Transplant       Date:  2004-05       Impact factor: 5.742

Review 6.  Chronic graft-versus-host disease.

Authors:  Stephanie J Lee; Georgia Vogelsang; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2003-04       Impact factor: 5.742

7.  Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse.

Authors:  Stephanie J Lee; John P Klein; A John Barrett; Olle Ringden; Joseph H Antin; Jean-Yves Cahn; Matthew H Carabasi; Robert Peter Gale; Sergio Giralt; Gregory A Hale; Osman Ilhan; Philip L McCarthy; Gerard Socie; Leo F Verdonck; Daniel J Weisdorf; Mary M Horowitz
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

8.  Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment.

Authors:  R Storb; R L Prentice; C D Buckner; R A Clift; F Appelbaum; J Deeg; K Doney; J A Hansen; M Mason; J E Sanders; J Singer; K M Sullivan; R P Witherspoon; E D Thomas
Journal:  N Engl J Med       Date:  1983-02-10       Impact factor: 91.245

9.  Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings.

Authors:  R Storb; R L Prentice; K M Sullivan; H M Shulman; H J Deeg; K C Doney; C D Buckner; R A Clift; R P Witherspoon; F A Appelbaum; J E Sanders; P S Stewart; E D Thomas
Journal:  Ann Intern Med       Date:  1983-04       Impact factor: 25.391

10.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

Authors:  H M Shulman; K M Sullivan; P L Weiden; G B McDonald; G E Striker; G E Sale; R Hackman; M S Tsoi; R Storb; E D Thomas
Journal:  Am J Med       Date:  1980-08       Impact factor: 4.965

View more
  215 in total

1.  Pre-transplantation risk factors to develop sclerotic chronic GvHD after allogeneic HSCT: a multicenter retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

Authors:  M Y Detrait; S Morisset; R Peffault de Latour; I Yakoub-Agha; R Crocchiolo; R Tabrizi; J-O Bay; P Chevalier; F Barraco; N Raus; S Vigouroux; L Magro; M Mohty; N Milpied; D Blaise; G Socié; M Michallet
Journal:  Bone Marrow Transplant       Date:  2014-11-03       Impact factor: 5.483

Review 2.  How we treat chronic graft-versus-host disease.

Authors:  Mary E D Flowers; Paul J Martin
Journal:  Blood       Date:  2014-11-14       Impact factor: 22.113

3.  Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantation.

Authors:  Nandita Khera; Barry Storer; Mary E D Flowers; Paul A Carpenter; Yoshihiro Inamoto; Brenda M Sandmaier; Paul J Martin; Stephanie J Lee
Journal:  J Clin Oncol       Date:  2011-12-05       Impact factor: 44.544

4.  Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.

Authors:  Aristeidis Chaidos; Scott Patterson; Richard Szydlo; Mohammed Suhail Chaudhry; Francesco Dazzi; Edward Kanfer; Donald McDonald; David Marin; Dragana Milojkovic; Jiri Pavlu; John Davis; Amin Rahemtulla; Katy Rezvani; John Goldman; Irene Roberts; Jane Apperley; Anastasios Karadimitris
Journal:  Blood       Date:  2012-02-27       Impact factor: 22.113

Review 5.  Cutaneous graft-versus-host disease--clinical considerations and management.

Authors:  Peggy A Wu; Edward W Cowen
Journal:  Curr Probl Dermatol       Date:  2012-02-17

6.  A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms.

Authors:  Carolina Martínez-Laperche; Elena Buces; M Carmen Aguilera-Morillo; Antoni Picornell; Milagros González-Rivera; Rosa Lillo; Nazly Santos; Beatriz Martín-Antonio; Vicent Guillem; José B Nieto; Marcos González; Rafael de la Cámara; Salut Brunet; Antonio Jiménez-Velasco; Ildefonso Espigado; Carlos Vallejo; Antonia Sampol; José María Bellón; David Serrano; Mi Kwon; Jorge Gayoso; Pascual Balsalobre; Álvaro Urbano-Izpizua; Carlos Solano; David Gallardo; José Luis Díez-Martín; Juan Romo; Ismael Buño
Journal:  Blood Adv       Date:  2018-07-24

Review 7.  Mixing old and young: enhancing rejuvenation and accelerating aging.

Authors:  Ashley Lau; Brian K Kennedy; James L Kirkland; Stefan G Tullius
Journal:  J Clin Invest       Date:  2019-01-02       Impact factor: 14.808

8.  Birth order and transplantation outcome in HLA-identical sibling stem cell transplantation: an analysis on behalf of the Center for International Blood and Marrow Transplantation.

Authors:  Christiane Dobbelstein; Kwang Woo Ahn; Michael Haagenson; Gregory A Hale; Jon J van Rood; David Miklos; Edmund K Waller; Stephen R Spellman; Marcelo Fernandez-Vina; Arnold Ganser; Mahmoud Aljurf; Martin Bornhaeuser; Vikas Gupta; Susan R Marino; Marilyn S Pollack; Vijay Reddy; Matthias Eder; Stephanie J Lee
Journal:  Biol Blood Marrow Transplant       Date:  2013-02-01       Impact factor: 5.742

9.  Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups.

Authors:  Yoshihiro Inamoto; Fumihiko Kimura; Junya Kanda; Junichi Sugita; Kazuhiro Ikegame; Hideki Nakasone; Yasuhito Nannya; Naoyuki Uchida; Takahiro Fukuda; Kosuke Yoshioka; Yukiyasu Ozawa; Ichiro Kawano; Yoshiko Atsuta; Koji Kato; Tatsuo Ichinohe; Masami Inoue; Takanori Teshima
Journal:  Haematologica       Date:  2016-08-04       Impact factor: 9.941

10.  Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans.

Authors:  Hideki Nakasone; Lu Tian; Bita Sahaf; Takakazu Kawase; Kelsi Schoenrock; Spenser Perloff; Christine E Ryan; Jed Paul; Rakesh Popli; Fang Wu; Joanne M Otani; John Coller; Edus H Warren; David B Miklos
Journal:  Blood       Date:  2015-03-12       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.